US equities |
SPCX $167.10 ▲+5.12% NVDA $237.12 ▲+1.35% MU $1,063.88 ▼-1.02% TSLA $378.16 ▲+2.04% MSFT $527.01 ▲+1.83% INTC $116.70 ▼-2.21% SNDK $1,714.49 ▼-0.32% META $745.92 ▲+2.45%
FinancialContent

Zymeworks Inc. - Common Stock (NQ:ZYME)

25.99 +0.84 (+3.34%)
Delayed Quote Updated: 11:23 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zymeworks Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
5 Analysts Have This To Say About Zymeworks ↗
 
Via Benzinga
News headline image
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Broadcom To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
This RPM International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit ↗
Zymeworks discontinues ZW171 development after Phase 1 findings, refocusing on other cancer therapies in its pipeline, including ZW191 and ZW251. 
Via Benzinga
News headline image
Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update ↗
The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer. 
Via Stocktwits
News headline image
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
From Zymeworks Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are moving after the closing bell on Friday? ↗
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Company to participate in investor conferences in July and August 
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge ↗
Zymeworks is entitled to receive a $20 million milestone payment in connection with the NMPA approval of zanidatamab as part of its agreement with BeOne Medicines. 
Via Stocktwits
News headline image
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
TD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer Therapy ↗
The research firm expects key clinical data in late 2025 and sees Ziihera royalties funding pipeline development. 
Via Stocktwits
News headline image
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >